Liu Zhenjie, Chen Jinyi, Xu Xin, Lan Fen, He Minzhi, Shao Changming, Xu Yongshan, Han Pan, Chen Yibing, Zhu Yongbin, Huang Man
Department of Vascular Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Intensive Care Unit, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Front Cardiovasc Med. 2022 Jun 3;9:875021. doi: 10.3389/fcvm.2022.875021. eCollection 2022.
Both venoarterial extracorporeal membrane oxygenation (VA-ECMO) and percutaneous mechanical thrombectomy (PMT) are increasingly used to treat acute life-threatening pulmonary embolism (PE). However, there are little data regarding their effectiveness. This study aimed to present the short-term outcomes after managing nine patients with acute life-threatening massive or submassive PE by VA-ECMO with or without complemented PMT and propose a preliminary treatment algorithm.
This study was a single-center retrospective review of a prospectively maintained registry. It included nine consecutive patients with massive or submassive pulmonary embolism who underwent VA-ECMO for initial hemodynamic stabilization, with or without PMT, from August 2018 to November 2021.
Mean patient age was 54.7 years. Four of nine patients (44.4%) required cardiopulmonary resuscitation before or during VA-ECMO cannulation. All cannulations (100%) were successfully performed percutaneously. Overall survival was 88.9% (8 of 9 patients). One patient died from a hemorrhagic stroke. Of the survivors, the median ECMO duration was 8 days in patients treated with ECMO alone and 4 days in those treated with EMCO and PMT. Five of nine patients (55.6%) required concomitant PMT to address persistent right heart dysfunction, with the remaining survivors (44.4%) receiving VA-ECMO and anticoagulation alone. For survivors receiving VA-ECMO plus PMT, median hospital lengths of stay were 7 and 13 days, respectively.
An ECMO-first strategy complemented with PMT can be performed effectively and safely for acute life-threatening massive or submassive PE. VA-ECMO is feasible for initial stabilization, serving as a bridge to therapy primarily in inoperable patients with massive PE. Further evaluation in a larger cohort of patients is warranted to assess whether VA-ECMO plus PMT may offer an alternative or complementary therapy to thrombolysis or surgical thrombectomy.
Single-center retrospective review of a prospectively maintained registry.
静脉-动脉体外膜肺氧合(VA-ECMO)和经皮机械血栓切除术(PMT)越来越多地用于治疗危及生命的急性肺栓塞(PE)。然而,关于它们有效性的数据很少。本研究旨在介绍9例危及生命的急性大面积或次大面积PE患者在接受VA-ECMO联合或不联合PMT治疗后的短期结果,并提出初步治疗算法。
本研究是对前瞻性维护的登记册进行的单中心回顾性研究。纳入了2018年8月至2021年11月期间连续9例因初始血流动力学稳定而接受VA-ECMO治疗的大面积或次大面积肺栓塞患者,其中部分患者联合或未联合PMT。
患者平均年龄为54.7岁。9例患者中有4例(44.4%)在VA-ECMO插管前或插管期间需要心肺复苏。所有插管(100%)均通过经皮成功完成。总体生存率为88.9%(9例患者中的8例)。1例患者死于出血性中风。在幸存者中,单纯接受ECMO治疗的患者ECMO持续时间中位数为8天,接受ECMO和PMT治疗的患者为4天。9例患者中有5例(55.6%)需要同时进行PMT以解决持续的右心功能不全,其余幸存者(44.4%)仅接受VA-ECMO和抗凝治疗。对于接受VA-ECMO加PMT治疗的幸存者,住院时间中位数分别为7天和13天。
对于危及生命的急性大面积或次大面积PE,以ECMO为先并辅以PMT的策略可以有效且安全地实施。VA-ECMO对于初始稳定是可行的,主要作为无法手术的大面积PE患者的治疗桥梁。有必要在更大规模的患者队列中进行进一步评估,以确定VA-ECMO加PMT是否可以为溶栓或手术取栓提供替代或补充治疗。
对前瞻性维护的登记册进行的单中心回顾性研究。